Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M.
Palumbo A, et al. Among authors: cavallo f.
Blood. 2004 Nov 15;104(10):3052-7. doi: 10.1182/blood-2004-02-0408. Epub 2004 Jul 20.
Blood. 2004.
PMID: 15265788
Free article.
Clinical Trial.